---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-037747"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T05:01:52.513563+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Maze Therapeutics enters $200M Hercules Capital term loan facility; initial $40M funded

## Summary
- Up to $200M senior secured term loan from Hercules Capital; initial $40M (Tranche 1A) funded Feb 4, 2026.
- Interest rate based on WSJ prime rate with floors 7.95%–9.25%; interest-only period up to 60 months with milestones.
- Maturity Feb 1, 2031; prepayment premiums up to 3% within first 12 months, plus exit fee of 3.95%–6.45%.
- Covenants include minimum cash requirement of 50% of outstanding loan unless market cap >$450M or >$750M.
- Prior Banc of California loan terminated and security released concurrent with this facility.

## SEC filing metadata
- accession: 0001193125-26-037747
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 1.02, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312526037747/0001193125-26-037747-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312526037747/d34522d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-037747
- JSON: https://secwatch.observer/filing/0001193125-26-037747.json
- Plain text: https://secwatch.observer/filing/0001193125-26-037747.txt

## Key facts
- Debt Financings
  Maze Therapeutics, Inc. incurred term loan of up to $200.0 million with Hercules Capital, Inc. at ‘prime rate’ as reported in the Wall Street Journal, with interest rate floors t maturing February 1, 2031.
  - Instrument: term loan
  - Principal: up to $200.0 million
  - Counterparty: Hercules Capital, Inc.
  - Rate: ‘prime rate’ as reported in the Wall Street Journal, with interest rate floors t
  - Maturity: February 1, 2031
  - Event: incurrence
  source text: On February 4, 2026 (the “ Closing Date ”), Maze Therapeutics, Inc. (the “ Company ”) entered into that certain Loan and Security Agreement (the “ Hercules Loan Agreement ”), by and among the Company, as borrower, the lenders from time to time party thereto, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the lenders party thereto, which provides for a senior secured term loan facility in an aggregate principal amount of up to $200.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312526037747/0001193125-26-037747-index.htm
- Material Agreements
  Maze Therapeutics, Inc. entered into Loan and Security Agreement with Hercules Capital, Inc. valued at up to $200.0 million (effective 2026-02-04).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc.
  - Value: up to $200.0 million
  - Effective: 2026-02-04
  source text: On February 4, 2026 (the “ Closing Date ”), Maze Therapeutics, Inc. (the “ Company ”) entered into that certain Loan and Security Agreement (the “ Hercules Loan Agreement ”), by and among the Company, as borrower, the lenders from time to time party thereto, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the lenders party thereto, which provides for a senior secured term loan facility in an aggregate principal amount of up to $200.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312526037747/0001193125-26-037747-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.